Molecules Engineered Against Oncogenic Proteins and Cancer: Discovery, Design, and Development

Molecules Engineered Against Oncogenic Proteins and Cancer is a comprehensive review of the latest molecular advances in cancer treatment, featuring 91 small molecule kinase/KRAS inhibitors, 80 of which are FDA-approved. It includes information on the structural formulas of over 100 kinase/KRAS inhibitors in clinical trials, as well as the drug discovery process, mutated protein kinases as oncoproteins, and the history of oncoprotein inhibitors. It is an essential resource for researchers and students in bioscience, medicine, chemistry, and oncology, as well as for those at industrial companies involved in therapeutic discovery.

Format: Hardback
Length: 400 pages
Publication date: 09 August 2023
Publisher: John Wiley & Sons Inc

A comprehensive exploration of the most recent molecular breakthroughs in cancer treatment is presented in Molecules Engineered Against Oncogenic Proteins and Cancer. This extensive review encompasses 91 small molecule kinase/KRAS inhibitors, of which 80 have received FDA approval, highlighting the significant scientific advancements that have revolutionized the field of cancer treatment. These inhibitors play a pivotal role in specifically blocking oncogene-induced carcinogenic proteins, leading to remarkable improvements in cancer treatment outcomes. Furthermore, the book provides detailed structural formulas of over 100 kinase/KRAS inhibitors currently in clinical trials, offering valuable insights into their molecular characteristics and mechanisms of action. Authored by a renowned chemist, Molecules Engineered Against Oncogenic Proteins and Cancer delves into various aspects of this field. It explores the structures, functions, and relevance of these molecules to cancer, shedding light on the drug discovery process and molecular intricacies of drug action. The book also delves into the role of mutated protein kinases as oncoproteins and their targets for inhibition, highlighting the discoveries made in developing antitumor antikinase agents. The historical context of oncoprotein inhibitors and their contributions to advancing the treatment and understanding of cancer are explored, along with the challenges and opportunities in the field. Additionally, Molecules Engineered Against Oncogenic Proteins and Cancer offers a glimpse into the future of this dynamic field, discussing effective strategies for innovation, ongoing research endeavors, and potential breakthroughs. This essential resource is invaluable for researchers, students, professionals, and industry stakeholders in bioscience, medicine, chemistry, and oncology, as well as those engaged in therapeutic discovery. By combining the most significant recent discoveries in a unique and practical manner, Molecules Engineered Against Oncogenic Proteins and Cancer serves as a vital reference for advancing our understanding and combating cancer.

Weight: 1192g
Dimension: 223 x 286 x 27 (mm)
ISBN-13: 9781394207084